A phase 3 trial failed to find progression-free survival among lung cancer patients, Bristol Myers Squibb said May 10.
The study tested BMS' Opdivo with concurrent chemoradiotherapy followed by both Opdivo and Yervoy or Opdivo by itself. Researchers compared outcomes from that cohort to chemoradiotherapy followed by durvalumab.
Opdivo has about two dozen approved cancer indications, with some of them including antibody Yervoy. This trial focused on 925 patients with unresectable stage III non-small cell lung cancer.
The drugmaker said it will work with investigators to share more findings from the study.